MarketFriction

Glenmark Pharmaceuticals Ltd

NSE GLENMARK · BSE 532296 · Pharmaceuticals
₹2,331.00 -0.16%
NSE close2026-10-01
52 week range1,792.60 - 2,537.60
Market cap₹68,905 Cr.
P/E22.1
Nifty 200Nifty 500Nifty Midcap 50Nifty Midcap 100Midcap 150Nifty PharmaNifty Healthcare Index No price band Delivery 67.4%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales3,2072,5073,0633,2443,4343,3883,2563,2646,0473,9013,7714,018
Expenses2,7452,7152,5592,6562,8322,7872,6952,6843,6873,0313,0083,214
Operating Profit462-2095045886026005615812,360870763805
OPM %14%-8%16%18%18%18%17%18%39%22%20%20%
Other Income-20587351313931-361-297-1,184-140-18466
Interest121134149404852675866414354
Depreciation141147151118120123125130141154148173
Profit before tax-6-403555462473456896967534388643
Tax %997%-18%319%26%25%24%45%51%37%24%22%25%
Net Profit-62-331-1,214340354348447610403301483
EPS in Rs-2.90-12.45-43.1712.0612.5512.330.161.6621.6314.2910.6817.11
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales7,5629,0799,0749,86510,64110,94412,30511,58311,81313,32216,98317,737
Expenses6,1257,0437,4578,2808,9428,8609,9789,94810,61810,97012,41012,940
Operating Profit1,4372,0371,6171,5861,6992,0842,3271,6351,1952,3514,5724,797
OPM %19%22%18%16%16%19%19%14%10%18%27%27%
Other Income20-448937519195-101-10336-259-1,805-1,443
Interest179237286335377353298349516207209204
Depreciation234264302326417444487569582486573617
Profit before tax1,0441,4911,1191,3011,0961,3821,4417074341,3991,9852,533
Tax %29%26%28%29%29%30%31%47%430%25%31%
Net Profit7431,109804925776970994377-1,4341,0471,3621,798
EPS in Rs26.3339.2928.4932.7827.5034.3833.3710.53-53.2237.1148.2663.71
Dividend Payout %8%5%7%6%9%7%7%24%-5%7%10%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth8%9%14%33%
Compounded Profit Growth12%19%61%134%
Stock Price CAGR10%37%42%25%
Return on Equity7%2%-3%24%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital272828282828282828282828
Reserves1,7563,6014,4645,1355,5776,0427,0369,0589,4467,8208,82110,484
Borrowings3,8003,9884,7244,6394,4494,8694,9863,9624,6081,2312,473594
Other Liabilities2,7262,5752,5482,7933,2353,7293,5244,0035,2895,2794,6698,801
Total Liabilities8,30910,19311,76412,59513,28914,66815,57517,05219,37114,35815,99119,907
Fixed Assets2,0152,5942,7553,0303,6705,0295,1295,8875,4224,2104,4875,915
CWIP4775437081,1221,3991,2221,3821,0101,190662835909
Investments1717161530252550457905642
Other Assets5,7997,0398,2858,4298,1908,3939,04010,10512,7158,69710,61313,041
Total Assets8,30910,19311,76412,59513,28914,66815,57517,05219,37114,35815,99119,907
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity4823456571,6481,3241,3921,1311,109625-265-8283,445
Cash from Investing Activity-712-950-1,001-1,003-883-774-662-316-5154,38758-1,237
Cash from Financing Activity199699543-468-739-445-442-520-77-3,906787-2,709
Net Cash Flow-3193199177-297174282723221517-501
Free Cash Flow-56-544-7662571261645632075-1,162-1,5762,090
CFO/OP66%57%67%124%111%109%79%72%77%65%-6%92%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days1401209794818386921155792107
Inventory Days247249299244244211230208203208254264
Days Payable379308243225241210226190172210256288
Cash Conversion Cycle861152113858490110147569083
Working Capital Days47511259964546765141-24481
ROCE %16%19%21%15%15%14%15%16%10%12%19%40%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters46.65%46.65%46.65%46.65%46.65%46.65%46.65%46.64%46.64%46.65%46.65%46.65%
FIIs24.79%23.71%21.38%20.98%23.05%23.51%23.15%20.62%20.73%19.20%20.35%20.89%
DIIs10.31%10.92%13.36%13.93%13.21%13.85%14.60%17.64%18.61%20.09%19.28%18.60%
Government0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%0.04%
Public18.21%18.70%18.58%18.42%17.06%15.96%15.56%15.05%13.97%14.02%13.70%13.81%
No. of Shareholders2,32,6852,09,9311,99,4511,92,6301,93,9491,95,0591,92,7241,90,2101,98,7892,01,5841,96,1052,11,418

Fundamentals

Market Cap₹ 68,905 Cr.
Current Price₹ 2,442
Stock P/E22.1
Book Value₹ 372
ROCE39.8 %
ROE23.6 %
Dividend Yield0.20 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)33%
Compounded Profit Growth (TTM)134%
Consolidated figures.
Valuation
Market capRs 65,781 Cr
Enterprise valueRs 65,198 Cr
P/E (TTM)36.59x
Price to book6.26x
Price to sales3.71x
EV / EBITDA19.44x
EV / EBIT23.82x
EV / sales3.68x
Price to cash flow19.09x
Earnings yield2.73%
Dividend yield0.21%
P/E, 3-year average42.85x
P/B, 3-year average4.69x
P/E, 5-year average35.76x
P/B, 5-year average3.37x
Profitability
Operating margin (excl. other income)26.92%
Operating margin (incl. other income)16.29%
EBITDA margin18.91%
Pre-tax margin14.28%
Net profit margin10.14%
Net margin, latest quarter12.02%
ROE14.07%
ROCE19.56%
ROA7.59%
ROE, 3-year average3.09%
ROCE, 3-year average14.50%
ROA, 3-year average1.86%
ROE, 5-year average4.83%
ROCE, 5-year average13.03%
ROA, 5-year average2.60%
ROIC (approx.)18.92%
Tax rate31.38%
Other income / net worth-17.18%
Growth
Sales growth (latest year)27.48%
Profit growth (latest year)30.06%
Sales CAGR, 3 years13.60%
Sales CAGR, 5 years9.19%
Profit CAGR, 3 years66.09%
Profit CAGR, 5 years7.02%
Sales growth QoQ6.57%
Profit growth QoQ60.22%
Sales growth YoY (latest quarter)23.10%
Profit growth YoY (latest quarter)930.34%
Per share
EPS (TTM)Rs 63.71
EPS (latest year)Rs 48.26
EPS (latest quarter)Rs 17.11
EPS, 3-year averageRs 10.72
EPS, 5-year averageRs 15.21
Book value per shareRs 372.50
Sales per shareRs 628.51
Cash flow per shareRs 122.08
Free cash flow per shareRs 74.06
Dividend per share (latest year)Rs 5.00
Dividend per share, 3-year averageRs 3.33
Dividend per share, 5-year averageRs 3.00
Dividends
Dividend payout10.36%
Dividend payout, 3-year average8.55%
Dividend payout, 5-year average12.08%
Efficiency
Asset turnover0.85x
Fixed asset turnover2.87x
Inventory turnover1.63x
Inventory days224 days
Debtor days107 days
Debtors turnover3.42x
Creditor days288 days
Cash conversion cycle83 days
Working capital days81 days
Leverage
Total debtRs 594 Cr
Cash and bankRs 1,176 Cr
Net debtRs -583 Cr
Debt to equity0.06x
Net debt / EBITDA-0.17x
Interest coverage13.38x
Current ratio (filing 2026-03-31)1.77x
Quick ratio (filing 2026-03-31)1.23x
Trade payables (filing 2026-03-31)Rs 3,744 Cr
Owners' fund to total sources52.81%
Debt to assets2.98%
Cash flow
Cash from Operating Activity (latest year)Rs 3,445 Cr
Cash from Investing Activity (latest year)Rs -1,237 Cr
Cash from Financing Activity (latest year)Rs -2,709 Cr
Net Cash Flow (latest year)Rs -501 Cr
Free cash flow (latest year)Rs 2,090 Cr
FCFE (approx.: FCF + change in debt)Rs 211 Cr
Cash from ops / profit, 5 years1.74x
Sales to cash flow4.93x
Statement figures
Net sales (TTM)Rs 17,737 Cr
Net sales (latest year)Rs 16,983 Cr
Sales (latest quarter)Rs 4,018 Cr
Operating profit excl. other income (latest year)Rs 4,572 Cr
Operating profit (latest quarter)Rs 805 Cr
Other income (TTM)Rs -1,443 Cr
EBITDA (TTM)Rs 3,354 Cr
PBDT (TTM)Rs 3,149 Cr
Profit before tax (TTM)Rs 2,533 Cr
Tax (latest year)Rs 623 Cr
Net profit (TTM)Rs 1,798 Cr
Net profit (latest year)Rs 1,362 Cr
Net profit (latest quarter)Rs 483 Cr
Depreciation (TTM)Rs 617 Cr
Depreciation (latest quarter)Rs 173 Cr
Interest (TTM)Rs 204 Cr
Cost of goods sold (latest year)Rs 5,584 Cr
Total expenditure (latest year)Rs 12,410 Cr
Total income (latest year)Rs 15,177 Cr
Share capitalRs 28 Cr
ReservesRs 10,484 Cr
Shareholders' fundsRs 10,512 Cr
Total assetsRs 19,907 Cr
Net blockRs 5,915 Cr
Capital work in progressRs 909 Cr
InvestmentsRs 42 Cr
ReceivablesRs 4,963 Cr
InventoryRs 3,431 Cr
Other liabilitiesRs 8,801 Cr
Shares outstanding (crore)28.22
Ownership
Promoter holding46.65% (+0.01 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 36.6 is at the 71th percentile of its own 8.5-year range (median 17.1, low 6.3, high 110.2).
P/B 6.26 is at the 91th percentile (median 2.76).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodGLENMARKNifty 50Difference
1 week-4.1%-2.8% -1.3 pts
1 month-5.6%-6.8% +1.1 pts
3 months+5.4%-7.6% +13.0 pts
6 months+9.3%+0.4% +8.9 pts
1 year+14.8%-9.9% +24.7 pts
2 years+36.1%-13.6% +49.7 pts
3 years+172.5%+14.2% +158.3 pts
5 years+354.3%+27.9% +326.4 pts
222 mutual fund schemes hold about ₹11,464 Cr. Over three months 64 bought more and 52 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
HDFC Mid Cap Fund3.07%3,325 -1%
Invesco India Midcap Fund2.91%462 -8%
Invesco India Contra Fund2.04%422 +3%
Invesco India Large & Mid Cap Fund2.69%316 -4%
ICICI Pru Arbitrage Fund0.84%294 -5%
SBI Arbitrage Fund0.62%292 +1%
Bandhan Large & Mid Cap Fund1.37%288 +15%
Kotak Arbitrage Fund(M0.36%275 -9%
HDFC Large & Mid Cap Fund0.86%260 +3%
Bandhan Small Cap Fund0.67%229 -11%
HDFC Balanced Advantage Fund0.20%219 +6%
Edelweiss Arbitrage Fund1.32%196 +5%
Quant Flexi Cap Fund2.62%193 +100%
UTI Arbitrage Fund1.64%183 +10%
Mirae Asset Healthcare Fund4.99%177 -22%
Nippon India Arbitrage Fund0.99%174 +21%
Nippon India Arbitrage Fund(M0.99%168 +21%
HDFC Manufacturing Fund1.44%153 -13%
Tata Mid Cap Fund2.38%149 +0%
UTI Nifty200 Momentum 30 Index Fund1.75%148 +5%
Quant Large & Mid Cap Fund4.11%143 +100%
Mahindra Manulife Mid Cap Fund2.59%140 +11%
Aditya Birla SL Arbitrage Fund0.51%140 -3%
HDFC Arbitrage Fund(M0.50%128 +2%
Tata Arbitrage Fund0.50%125 -12%

Red flags

F-score 8 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2023-09-20Mr. Praveen D KurkalEmployees/Designated Employesell1,000Rs 0.09 CrMarket Sale
2023-09-20Mr. Praveen D KurkalEmployees/Designated Employesell1,000Rs 0.09 CrMarket Sale
2023-09-20Mr. Praveen D KurkalEmployees/Designated Employesell500Rs 0.04 CrMarket Sale
2021-11-23Robin PintoPromoter Groupbuy250Rs 0.01 CrMarket Purchase
2021-11-15SRIDHAR GORTHIDirectorsell559Rs 0.03 CrMarket Sale
2021-09-27RAYNA MARIE SALDANHAImmediate relativeother10,000Gift
2021-09-27NEHA SALDANHAPromoter Groupother20,000Gift
2021-09-27AISHA LOUISE SALDANHAImmediate relativeother10,000Gift
2021-09-24Glenn Mario SaldanhaPromotersbuy9,800Rs 0.50 CrMarket Purchase
2021-09-22Cherylann Maria PintoPromotersbuy1,950Rs 0.10 CrMarket Purchase
2021-06-23Glenn Mario SaldanhaPromotersbuy7,800Rs 0.50 CrMarket Purchase
2021-06-22Glenn Mario SaldanhaPromotersbuy2,800Rs 0.18 CrMarket Purchase
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹4,018 Cr +23.1% vs Jun 2025. Net profit ₹483 Cr +927.7%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Zydus Lifesciences Ltd119,75024.621.1 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-08-31Dividend - Rs 2.50 Per Share
2025-10-03Interim Dividend - Rs 2.50 Per Share
2025-09-15Dividend - Rs 2.50 Per Share
2024-09-13Dividend - Rs 2.50 Per Share
2023-09-18Dividend - Rs 2.50 Per Share
2022-09-12Annual General Meeting/Dividend - Rs 2.50 Per Share
2021-09-08 Annual General Meeting/Dividend - Rs 2.50 Per Share
2020-09-17 Annual General Meeting/Dividend - Rs 2.50 Per Share
2019-09-19 Annual General Meeting/Dividend - Rs 2 Per Share
2018-09-19 Annual General Meeting/Dividend Rs 2 Per Share
2017-09-20 Annual General Meeting/Dividend - Rs 2/- Per Share
2016-08-03 Annual General Meeting/ Dividend - Rs 2/- Per Share
2015-09-10 Annual General Meeting/ Dividend - Rs 2/- Per Share
2014-07-10Annual General Meeting / Dividend - Rs 2/- Per Share
2013-07-18Annual General Meeting / Dividend - Rs 2/- Per Share
2012-07-19Annual General Meeting / Dividend Rs 2 Per Share
2011-07-28Annual General Meeting And Dividend Re.0.40 Per Share
2010-09-16Annual General Meeting And Dividend Re.0.40 Per Share
2009-09-10Agm/Div-Re.0.40 Per Share
2008-09-18Annual General Meeting
2007-11-07Interim Dividend-70% Purpose Revised
2007-09-10Agm/Fv Split Rs.2 To Re.10.5000
2007-01-04Interim Dividend - 40%
2006-09-25Agm
DateTypeWhat it says
2026-09-23Press ReleaseA press release dated September 23, 2026, titled "Glenmark Pharmaceuticals receives Establishment Inspection Report (EIR) from U.S. FDA for its Goa fa...
2026-09-21Concall / analyst meetSchedule of meet
2026-09-11Shareholder meetingProceedings of Annual General Meeting held on September 11, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along w...
2026-09-11Press ReleaseA press release dated September 11, 2026, titled "Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil ".
2026-09-11Credit RatingCredit Rating
2026-08-21Press ReleaseA press release dated August 21, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL)...
2026-08-20Press ReleaseA press release dated August 20, 2026, titled "Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50...
2026-08-13General UpdatesLetter to shareholders whose email address are not registered providing the Web Link of Integrated Annual Report
2026-08-13Shareholder meetingNotice of Annual General Meeting to be held on September 11, 2026
2026-08-11General UpdatesSettlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015
2026-08-10ESOP grantIntimation of Allotment of shares under the Employee Stock Option Plan 2016
2026-08-07Concall / analyst meetSchedule of meet
2026-08-05Concall / analyst meetTranscript
2026-08-03Concall / analyst meetLink of Recording
2026-07-31UpdatesInvestor Presentation.
2026-07-31Press ReleaseA press release dated July 31, 2026, titled "Press Release and Management Discussion & Analysis".
2026-07-31UpdatesRegulation 30(5) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 List of Officials.
2026-07-31Record DateRecord date for the purpose of Dividend is 31-Aug-2026.
2026-07-31Board meeting outcomeGlenmark Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
2026-07-28Press ReleaseA press release dated July 28, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL...
2026-07-21Concall / analyst meetSchedule of meet
2026-07-21Press ReleaseA press release dated July 21, 2026, titled "Glenmark Receives U.S. FDA Approval to Expand the Use of RYALTRIS® Nasal Spray for Children Aged 6 to Les...
2026-07-06Press ReleaseA press release dated July 06, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Olanzapine for Injection, 10 mg/vial, Single-Dose Vial".
2026-07-02Press ReleaseA press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ova...
2026-06-30General UpdatesU.S. FDA inspection
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.64
Max pain (expiry 2026-10-27)2,360
Largest call open interest at2,400
Largest put open interest at2,300
Implied volatility, at the money26.6%
Underlying at snapshot2,331.00
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-29761
2026-09-28249
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2021-01-04NCLATGlenmark Pharmaceuticals Ltd. VS Competition Commission of India & Anr.
2020-03-05NCLATGlenmark Pharmaceuticals Ltd. VS Competition Commission of India & Anr.
2019-12-05NCLATGlenmark Pharmaceuticals Ltd. VS Competition Commission of India & Anr.
2019-11-22NCLATGlenmark Pharmaceuticals Ltd. VS Competition Commission of India & Anr.
2019-08-21NCLATGlenmark Pharmaceuticals Ltd. VS Competition Commission of India & Anr.
2019-07-09NCLATGlenmark Pharmaceuticals Ltd. VS Competition Commission of India & Anr.
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd (GLENMARK) has a market capitalisation of Rs 68,905 Cr. at the 2026-10-01 close.

What is the P/E ratio of Glenmark Pharmaceuticals Ltd?

Glenmark Pharmaceuticals Ltd trades at a P/E of 22.1 on trailing twelve-month profit, at the 2026-10-01 close.

What were Glenmark Pharmaceuticals Ltd's latest quarterly results?

In the Jun 2026 quarter, Glenmark Pharmaceuticals Ltd sales was Rs 4,018 Cr (+23.1% vs Jun 2025) and net profit was Rs 483 Cr.

What is the 52-week high and low of Glenmark Pharmaceuticals Ltd?

The 52-week high is Rs 2,537.60 and the 52-week low is Rs 1,792.60.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03